Sat, Dec 20, 2014, 4:02 PM EST - U.S. Markets closed


% | $
Quotes you view appear here for quick access.

3D Systems Corporation Message Board

bemore4224 41 posts  |  Last Activity: Dec 18, 2014 7:56 PM Member since: Aug 17, 2010
SortNewest  |  Oldest  |  Highest Rated Expand all messages
  • Reply to

    new coverage

    by bemore4224 Dec 17, 2014 11:04 AM
    bemore4224 bemore4224 Dec 18, 2014 7:56 PM Flag

    I've spoken with several doctor friends who have worked with this company and they have spoken so highly of the employees and what a wonderful experience it was. The market does not have it right. Just feel this is a gem that hasn't been discovered.

    Sentiment: Strong Buy

  • Reply to

    Zack's comment on CTSO's....

    by bhakes_98 Dec 18, 2014 10:37 AM
    bemore4224 bemore4224 Dec 18, 2014 10:56 AM Flag

    Over the last several quarters CtyoSorbents (CTSOD) has been feverishly building out a distribution platform for its flagship device, CytoSorb, throughout Europe as well as parts of Asia and the Middle East. The company uses a small, highly experienced in-house sales team to cover Germany, Austria and Switzerland and utilizes third-party distributors to sell in 22 other countries, including Biocon, the largest biotech in India.

    But while CTSO has rapidly expanded their geographic reach which has included relationships with significant institutions in the international life sciences space, none of these partners bring the name recognition, marketing muscle or implied credibility that Fresenius does.

    Fresenius has marketing exclusivity of CytoSorb in France, Poland, Sweden, Denmark, Norway and Finland which brings the number of countries where CytoSorb will be available to 25. The deal includes minimum guaranteed orders. Fresenius is the largest dialysis provider in the world, providing dialysis services and dialysis equipment and supplies.

    Fresenius’ distribution reach including in France, which is the second largest market for medical devices in Europe, will almost certainly be a material needle-mover of CTSO’s revenue. But Fresenius brings much more than just a large dialysis service/equipment/supplies network. Fresenius is THE leader in dialysis, has a calling card to the largest and most prestigious hospitals and clinics, employs a highly experienced sales team and has the resources to support ongoing development and clinical case studies of CytoSorb.

    But even beyond that Fresenius has a reputation of leadership and quality in the space and one that they are unlikely to risk tainting if they had reservations about the utility of CytoSorb. The face of Fresenius now includes the face of CytoSorb. As such we view the relationship with Fresenius as one that is likely to provide more than just a significant increase to the geographic distribution footprint for CytoSorb (which alone is highly material). Fresenius gives both CytoSorbents and CytoSorb an additional significant vote of credibility.

    And credibility potentially gets CytoSorb used by the leading and most prestigious hospitals in these distribution territories. When it comes to building credible awareness, having influential key opinion leaders, medical institutions and device companies supporting utility of a novel device can provide one of the most effective marketing messages and spur much more widespread uptake.

    As we have noted in our ongoing coverage of CytoSorbents, building credible awareness has been at the heart of the company’s marketing strategy. As opposed to a “just trust us that our product works” followed by many novel device manufacturers, CTSO has been very methodical and deliberate in building evidenced-based support for the efficacy of its device. We think it is unlikely a company of Fresenius’ caliber would partner with CTSO had this early evidence not existed.

    And CTSO remains very focused on growing the clinical experience database. The company just recently launched a patient registry which houses case study data submitted by CytoSorb users for various indications. This type of evidence-based outcomes data can provide a compelling marketing message to clinicians considering adopting CytoSorb and, even prior to launch of the database, has almost certainly been a catalyst in driving demand for the device and helped to consummate major distribution agreements.

    And certain of these case studies have already been published in industry journals including a cardiac surgery study published in February in the journal Kardiotechnik which indicated CytoSorb can significantly reduce inflammatory response during cardiac surgery. And more recently, in December, two separate case studies were published in the peer-reviewed Indian Journal of Critical Care Medicine and the journal, Liver Transplantation. In both of these cases a critically ill patient with organ failure and near death eventually recovered following intervention with CytoSorb.

    So as we have discussed in our coverage of CytoSorbents, we view management’s marketing and awareness building strategy, which is based on clinical successes and evidence and not on a “just trust me” sales pitch, as having the greatest potential to drive demand for CytoSorb. And based on the rapid product sales growth (7 straight quarters of product revenue growth) and consummation of high-potential distribution agreements, we think it’s fair to conclude that this strategy is paying significant dividends. This deal with Fresenius is one which we think speaks particularly loud to CTSO’s successes and the growing confidence in the utility of CytoSorb.

    We continue to think the shares trade well below fair value and are maintaining our Outperform rating on CTSO and our (25:1 reverse-split adjusted) $12.50 price target.

    Sentiment: Strong Buy

  • Overall, we believe that Synergy offers investors exposure to industry-leading production growth and a solid balance sheet, a unique combination for a small-cap equity. In our view, the market under-appreciates the production potential from new completion techniques; capital efficiency of the mid- to extended-reach lateral program, which is just heating up; and, perhaps more importantly, management’s ability and desire to bring value forward. In addition, the company’s lean cost structure should help protect margins in the face of weaker commodity prices…

    Sentiment: Buy

  • bemore4224 by bemore4224 Dec 17, 2014 11:04 AM Flag

    *DJ Materialise NV Started at Outperform by Pacific Crest MTLS . Frustrating company-should be much higher.

    Sentiment: Strong Buy

  • Reply to


    by ctsoforlife Dec 15, 2014 4:01 PM
    bemore4224 bemore4224 Dec 15, 2014 6:14 PM Flag

    Our partner was probably testing the product and became convinced it as a winner.

    Sentiment: Strong Buy

  • Reply to

    cnbc fast money

    by bemore4224 Dec 12, 2014 12:18 PM
    bemore4224 bemore4224 Dec 12, 2014 3:03 PM Flag

    Surprising that she doesn't understand the difference. One would think going into this show and knowing who was going to be on it she would have read about it and would be well versed on the matter. Isn't she one of Cramers cronies? Or is that the lady on the noon show. Anyway Cramer said that he was not backing away from ONVO.

    Sentiment: Strong Buy

  • Reply to

    cnbc fast money

    by bemore4224 Dec 12, 2014 12:18 PM
    bemore4224 bemore4224 Dec 12, 2014 12:29 PM Flag


  • bemore4224 by bemore4224 Dec 12, 2014 12:18 PM Flag

    I listened to the interview and (i've been long since 7/13) was very pleased. I did not hear what the panel's response was-anyone? Thanks

    Sentiment: Strong Buy

  • Reply to

    MACK CEO & Pres. Mulroy buys 93,247 shares

    by bananafishmusic Dec 12, 2014 9:12 AM
    bemore4224 bemore4224 Dec 12, 2014 10:57 AM Flag

    Stock Screener: Symbol Begin Date: End Date:
    Buy/Sell Transaction Date Acceptance DateTime Issuer Name Issuer Trading Symbol Reporting Owner Name Reporting Owner Relationship Transaction Shares Price per Share Total Value Shares Owned Following Transaction Form
    Buy 2014-12-05 2014-12-09 17:19:53 MERRIMACK PHARMACEUTICALS INC MACK Stewart Edward J. officer 3,000 $1.7100 $5,130.0000 24,385 Form 4
    Sell 2014-12-05 2014-12-09 17:19:53 MERRIMACK PHARMACEUTICALS INC MACK Stewart Edward J. officer 3,000 $10.0000 $30,000.0000 21,385 Form 4
    Sell 2014-12-05 2014-12-09 17:14:49 MERRIMACK PHARMACEUTICALS INC MACK Mulroy Robert J. director officer 175,000 $9.8500 $1,723,750.0000 1,246,070 Form 4
    Buy 2014-12-05 2014-12-09 17:14:49 MERRIMACK PHARMACEUTICALS INC MACK Mulroy Robert J. director officer 175,000 $1.2500 $218,750.0000 1,421,070 Form 4
    Buy 2014-12-08 2014-12-09 17:14:49 MERRIMACK PHARMACEUTICALS INC MACK Mulroy Robert J. director officer 25,837 $1.2500 $32,296.2000 1,296,070 Form 4
    Buy 2014-12-08 2014-12-09 17:14:49 MERRIMACK PHARMACEUTICALS INC MACK Mulroy Robert J. director officer 49,163 $1.2500 $61,453.8000 1,295,230 Form 4
    Buy 2014-12-08 2014-12-09 17:14:49 MERRIMACK PHARMACEUTICALS INC MACK Mulroy Robert J. director officer 43,247 $1.7100 $73,952.4000 1,339,320 Form 4
    Sell 2014-12-08 2014-12-09 17:14:49 MERRIMACK PHARMACEUTICALS INC MACK Mulroy Robert J. director officer 25,000 $9.7300 $243,250.0000 1,270,230 Form 4
    Buy 2014-12-02 2014-12-04 12:14:53 MERRIMACK PHARMACEUTICALS INC MACK PORTER MICHAEL E director 8,000 $8.7100 $69,680.0000 633,164 Form 4

    Sentiment: Strong Buy

  • Reply to

    new HIV pill

    by bemore4224 Nov 26, 2014 3:14 PM
    bemore4224 bemore4224 Nov 29, 2014 3:05 PM Flag

    Gilead Sciences Inc. announced that it has submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for an investigational, once-daily single tablet regimen containing elvitegravir 150 mg, cobicistat 150 mg, emtricitabine 200 mg and tenofovir alafenamide (TAF) 10 mg (E/C/F/TAF) for the treatment of HIV-1 infection in adults. The data submitted in the NDA support the use of the regimen among adult and adolescent treatment-naïve HIV individuals, virologically suppressed patients who switch regimens and those with renal impairment. If approved, E/C/F/TAF would be Gilead’s first single tablet regimen to contain TAF.

    TAF is an investigational, novel prodrug of tenofovir, the active agent in Gilead’s Viread (tenofovir disoproxil fumarate). TAF is a more targeted form of tenofovir than Viread that has demonstrated high antiviral efficacy at a dose that is 10 times lower, as well as an improved renal and bone safety profile.

    “This TAF-based regimen has the potential to provide a range of HIV patients with a highly effective and well-tolerated new treatment option with a favorable safety profile,” said Norbert Bischofberger, PhD, Executive Vice President, Research and Development and Chief Scientific Officer, Gilead Sciences. “Gilead remains focused on advancing next-generation therapies that have the potential to improve HIV treatment over the long-term and TAF will be the cornerstone of future Gilead single tablet regimens.”

    The NDA for E/C/F/TAF is supported by 48-week data from two pivotal Phase 3 studies in which the regimen met its primary objective of non-inferiority compared to Gilead’s Stribild among treatment-naïve patients. In the studies, E/C/F/TAF demonstrated improved renal and bone safety compared to Stribild. The NDA is also supported by data from additional Phase 3 studies evaluating the TAF-based regimen among virologically suppressed patients who switched to E/C/F/TAF and among patients with renal impairment. In addition, the filing is supported by Chemistry, Manufacturing and Controls (CMC) information on the individual components and the co-formulated single tablet regimen.

    Gilead plans to submit a regulatory application for E/C/F/TAF in the European Union by the end of 2014.

    TAF and TAF-based regimens are investigational products and have not been determined safe or efficacious.

    Date: November 6, 2014

    Sentiment: Strong Buy

  • bemore4224 by bemore4224 Nov 26, 2014 3:14 PM Flag

    Anyone have an idea when the FDA should approve this drug? Thanks

    Sentiment: Strong Buy

  • Reply to

    Here's your problem, longs.

    by eleuthero58 Nov 24, 2014 11:55 AM
    bemore4224 bemore4224 Nov 24, 2014 1:35 PM Flag

    I missed Glen's reply-could you tell me what he said about the share price. Thanks I'm very long but getting frustrated with the sp- One would think someone would assume the debt and buy the company with what is ahead

  • bemore4224 bemore4224 Nov 17, 2014 2:45 PM Flag

    put the #$%$ on ignore; makes reading the posts much more enjoyable

    Sentiment: Strong Buy

  • Reply to


    by ken_rybicki Nov 15, 2014 1:25 PM
    bemore4224 bemore4224 Nov 15, 2014 3:18 PM Flag

    google it

  • bemore4224 bemore4224 Nov 13, 2014 3:16 PM Flag

    I'm surprised more orders from around the world. They have rules not allowing radio active materials with IMSC the only company to have devices that work that way. Once those orders start, sp will be much different.

    Sentiment: Strong Buy

  • bemore4224 bemore4224 Nov 12, 2014 5:25 PM Flag

    if I remember right there are 60-70% phds

  • bemore4224 bemore4224 Nov 12, 2014 3:33 PM Flag

    There are 25 job openings in Belgium alone. This company is expanding quickly.

  • bemore4224 by bemore4224 Nov 12, 2014 12:33 PM Flag

    This should be trading much higher

    Sentiment: Strong Buy

  • bemore4224 by bemore4224 Nov 6, 2014 9:59 AM Flag

    anyone have a clue as to when this will be approved?

  • bemore4224 bemore4224 Nov 3, 2014 7:23 PM Flag

    so you're the short pecker who gave the thumbs down

31.71-0.07(-0.22%)Dec 19 4:01 PMEST

Trending Tickers

Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.
3M Company
NYSEFri, Dec 19, 2014 4:04 PM EST
ImmunoGen, Inc.
NASDAQFri, Dec 19, 2014 4:00 PM EST